$1.55
-0.01 (-0.64%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PULM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 1 observational · 1 with posted results
Held by 1 tracked-famous manager (RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 1.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPANCT05667662Incidence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Low enrollment | Drug: Itraconazole Powder, Placebo | ABPA | 8 | 2024-02-27actual | 2024-04-02 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health AdultsNCT05351086Safety and TolerabilityRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PUR3100, Dihydroergotamine (D.H.E 45) · Other: Matching Placebo for PUR3100, Matching Placebo for D.H.E 45 | Healthy | 26 | 2022-09-22actual | 2022-12-23 |
| A Phase 1b Study of PUR1800 in Patients With COPDNCT04759807Incidence of treatment-emergent adverse events adult patients with stable COPD.Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Placebo Comparator, PUR1800 250 ug, PUR1800 500 ug | Chronic Obstructive Pulmonary Disease (COPD) | 18 | 2021-12-02actual | 2022-06-27 |
| Study in Adult Asthmatic Patients With Allergic Bronchopulmonary AspergillosisNCT03960606Incidence of treatment-emergent adverse eventsRandomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: COVID-19 Pandemic | Combination product: PUR1900, Placebo | Allergic Bronchopulmonary Aspergillosis | 7 | 2020-07-14actual | 2021-08-27 |
| Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With AsthmaNCT03479411Number of participants with treatment-related Adverse Events as assessed by CTCAE v4.0Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Itraconazole Powder, Itraconazole 200 mg | Asthma | 58 | 2018-06-28actual | 2018-07-27 |
| A PK Study to Evaluate PUR0200 and a Reference Product in Healthy SubjectsNCT02671825To assess PK parameter area under the plasma concentration versus time curve (AUC) of 5 formulations of PUR0200 compared to Reference ProductRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: PUR0200, Reference Product | Healthy | 42 | Mar 2016actual | 2016-11-11 |
| A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60NCT02280395Safety and tolerability will be determined by nature and incidence of adverse events and clinical laboratory values compared to saline control group. Wound site physical inspection tabulated result compared to saline control group.Randomized · Double-masked · Prevention | Phase 1/2 | Terminatedsponsor's stated reason: Company merger resulted in business decision to terminate the study. | Drug: RUT058-60, Sterile saline for irrigation | Postoperative Wound Infection-deep, Post Operative Wound Infection | 9 | Jun 2015actual | 2021-01-12 |
| 21 Day Cumulative Skin Irritation of RUT058-60NCT02198963results2016-02-04Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human SkinRandomized · Double-masked · Prevention | Phase 1 | Completed | Drug: Hypochlorous acid solution 106 mg/L, 0.1% (w/v) Sodium Lauryl Sulfate, 0.9% Physiological Saline, USP | Irritation/Irritant | 43 | Aug 2014actual | 2016-02-04 |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD PatientsNCT01921712Peak plasma concentration (Cmax) of PUR0200Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PUR0200, PUR0200 Placebo, Active comparator | Chronic Obstructive Pulmonary Disease (COPD) | 38 | Dec 2013actual | 2014-03-18 |
| Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal VolunteersNCT01690949Change from baseline in sputum cell counts and inflammatory markersRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: PUR118 | Chronic Obstructive Pulmonary Disease (COPD) | 24 | Apr 2013actual | 2013-07-19 |
| A Safety and Tolerability Study OF PUR118 In Subjects With Cystic FibrosisNCT01543191Safety and TolerabilityRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PUR118 | Cystic Fibrosis | 10 | Dec 2012actual | 2013-07-19 |
| Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118NCT01333904Safety and tolerability assessed by changes in clinical signs and symptoms, clinical safety laboratory tests, vital signs, ECG, spirometry, oxygen saturation, telemetry and adverse eventsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: PUR118 | Chronic Obstructive Pulmonary Disease | 90 | Jun 2012actual | 2012-09-07 |
| Effect of PUR003 on AsthmaNCT00989521Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PUR003, Placebo | Asthma, Lung Diseases, Bronchial Diseases | 7 | Oct 2011actual | 2011-11-22 |
| Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) SputumNCT01096173observational | — | Completed | — | Chronic Obstructive Pulmonary Disease | 10 | Jun 2010actual | 2011-04-11 |
| Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult SubjectsNCT00947687Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PUR003, Placebo | Healthy | 24 | Sep 2009actual | 2017-09-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19